The Accountable Care Consortium was envisioned as a vehicle through which the hospitals would eventually funnel all of their roughly $2.5 billion in annual contracts with health insurers and employers.
Before local hospitals slashed staff and expenses last year, they had been boosting the pay packages of their top executives faster than hospitals around the country. Seven of every 10 senior executives at the major hospital systems in Indianapolis saw their total compensation rise more than 10 percent from 2010 to 2012.
Since 2007, the cost of brand-name medicines has jumped, with prices doubling for dozens of established drugs that target everything from multiple sclerosis to cancer, blood pressure and even erections, according to an analysis conducted for Bloomberg News.
Jump IN for Healthy Kids has a budget of $1.5 million and hopes to identify and extend successful efforts to improve diet, activity and healthy choices among children and their families.
New tests have helped Roche Diagnostics grow its North American revenue, excluding its troubled diabetes care business, 23 percent over the past five years. But the money for diagnostic tests continues to go down in key areas, noted CFO Wayne Burris.
The court noted that after the government filed a second indictment March 12, the trade-secret theft claims against Guoqing Cao and Shuyu Li were changed to wire fraud, and aiding and abetting and conspiracy to commit wire fraud.
Next year, after Lilly completes its $5.4 billion acquisition of Novartis Animal Health, Elanco will contribute 17 percent of revenue—or one out of every six dollars flowing into Lilly’s coffers.
Indianapolis hospitals have begun to offer joint replacement surgeries to employers and insurers using “bundled prices.” That means, instead of billing piecemeal for each individual service and supply, the hospitals wrap everything needed from just before to just after surgery into a package deal.
Orthopedic device maker Zimmer Holdings Inc. is buying privately-held competitor Biomet Inc. in a cash-and-stock deal between the Warsaw-based companies valued at about $13.35 billion.
The drugmaker, which is weathering patent expirations, saw sales fall more slowly than expected for its antidepressant Cymbalta.
Tuesday’s blockbuster deal involving Indianapolis-based Eli Lilly and Co. was just the latest of several that have taken place since the beginning of the year.
Three Florida men who federal authorities say stole about $80 million in prescription drugs from an Eli Lilly and Co. warehouse in Connecticut have been charged with conspiracy and theft.
Wall Street analysts raised their eyebrows at the hefty price Eli Lilly and Co. will pay to acquire Novartis Animal Health, when compared to the value of the biggest player in the field.
The Indianapolis-based pharmaceutical maker gets a much-needed boost with FDA approval for gastric-cancer drug ramucirumab, which quickly could account for $1 billion in annual sales.
Still to be announced is what share of those 8 million enrollees were previously uninsured, and how many actually secured coverage by paying their first month’s premiums.
Mainstreet Property Group LLC plans to launch a new round of private placement fundraising on April 21 using a website run by Oregon-based CrowdStreet Inc. and a mix of traditional advertising in central Indiana.
Two of the state's top Republican lawmakers said Tuesday that they would like to see the federal government sign off on an expansion of Medicaid through the state's health care plan for low-income residents.
Evansville officials had pushed the location covering nearly six city blocks as a key for downtown redevelopment. The center that could draw some 2,000 health care students.
A top Indiana lawmaker, his family and investors in their company risked losing millions in future profits if a proposed ban on construction of new nursing homes in Indiana had become law this year, an Associated Press review has found.
Health insurers such as WellPoint Inc. that plan to hike prices on their Obamacare policies more than 10 percent in 2015 will have a much harder time than usual making their case to regulators.
